The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...
The transaction value is based on the SEC Form 4 weighted average purchase price ($20.76) for the trades executed. How significant was this sale relative to Jaen Juan C.'s historical trading? This was ...
Vancouver, British Columbia--(Newsfile Corp. - January 29, 2026) - Arcus Development Group Inc. (TSXV: ADG) ("Arcus" or the "Company") announces that it has completed a $2 million non-brokered unit ...
Arcus Biosciences has reported “encouraging clinical activity” in a phase 2 clinical trial of anti-TIGIT drug domvanalimab but held off on releasing any numbers from the study. The study is testing ...
Casdatifan data were better on every efficacy measure evaluated, across all four monotherapy cohorts (n=121) of the Phase 1/1b ARC-20 study in late-line metastatic kidney cancer, relative to published ...
In this first reported Phase 1b cohort, the etrumadenant-based combination was well tolerated with a composite overall response rate (ORR) of 41% in people previously treated for metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results